Our data indicate that Candesartan blocks PRL-3 phosphatase activity, can revert PRL-3 induced migration in HEK293T cells, and can reduce migration of colorectal cancer cells that express high levels of PRL-3, with no impact on migration in the same cells with PRL-3 knocked down via shRNA. This evidence concerns the gene PTP4A3 and colorectal cancer.